NJA-003

N/A

Report date: 2026/04/23 20:00:25

Base Information

Drug NameNJA-003

Drug Alias NameCD8⍺β T cell therapy(Shinobi Therapeutics)NJA-003

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyCell and gene therapy > Cell therapy > Source of cells > iPSC-derived

Mechanisms of ActionGlypican-3 modulatorsHLA Class I Histocompatibility Antigen, A-2 alpha Chain inhibitors

TargetsGlypican-3HLA Class I Histocompatibility Antigen, A-2 alpha Chain

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesJapan

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesShinobi Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesShinobi Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A